{"entity":{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","aka":["PDRadiopharma Inc.","PDR"],"tldr":"The Japanese radiopharmaceutical business that PeptiDream bought from FUJIFILM: it sells most of Japan's radioactive diagnostics and the therapies that go with them.","summary":"PDRadiopharma is a wholly owned subsidiary of PeptiDream, listed on its own company outline as \"PeptiDream Inc. 100%\". The legal entity started business on 28 March 2022, when the radiopharmaceutical business of FUJIFILM Toyama Chemical transferred to it, but the operation traces back to 1968 - which is why PDRadiopharma holds Japanese approvals granted long before the company existed.\n\nPeptiDream states the subsidiary commercialises 24 diagnostic and 8 therapeutic products in Japan. Its product pages list sodium pertechnetate generators, iodine-123 brain perfusion agents and sodium iodide I-131 therapy capsules; the PMDA's English approval list adds Lutathera and LysaKare (June 2021, originally approved to FUJIFILM Toyama Chemical), Amyvid, MyoMIBG-I123, Tauvid (December 2024) and Raiatt MIBG-I 131 (September 2025). That makes it the counterpart in Japan to Curium or Lantheus in the West: the domestic supplier of the routine agents on which the therapy business rests.","asOf":"2026-09-22","links":[{"label":"Company outline (shareholder PeptiDream Inc. 100%, business start 28 March 2022)","url":"https://www.pdradiopharma.com/en/about/outline/"},{"label":"PeptiDream company profile (radiopharmaceutical business through PDRadiopharma)","url":"https://www.peptidream.com/en/company/profile/"},{"label":"Diagnostic product list","url":"https://www.pdradiopharma.com/en/hcw/products/diagnostic/"},{"label":"Therapeutic product list","url":"https://www.pdradiopharma.com/en/hcw/products/therapeutic/"}],"tags":[],"related":["lutathera","f-18-flortaucipir","f-18-florbetapir","i-123-mibg-cardiac","radioactive-iodine","jsnm","pmda","i-123","i-131"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo, Japan","country":"JP","companyType":"radiopharma","website":"https://www.pdradiopharma.com/en/","founded":2022,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/pdradiopharma/","neighbours":{"drug":[{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/"},{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/"},{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/"}],"institution":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/"}],"isotope":[{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/"},{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/"}]}}